Abstract
To evaluate the efficacy and safety of the introduction of moxifloxacin into the recommended regimen for tuberculosis (TB) treatment. A meta-analysis was performed of nine eligible studies regarding the effect of moxifloxacin plus the recommended regimen compared to the recommended regimen alone for the treatment of TB. In the efficacy analysis, the overall odds ratio (OR) for sputum culture conversion was 1.895 (95% confidence interval (CI) 1.355-2.651, p=0.000), indicating that when moxifloxacin is combined with the recommended regimen, the rate of sputum culture conversion is elevated compared to the recommended regimen alone. The overall OR for recurrence was 0.516 (95% CI 0.342-0.920, p=0.022), suggesting that the introduction of moxifloxacin into the recommended regimen reduces TB relapse after treatment. In the safety analysis, the overall OR was estimated to be 1.001 (95% CI 0.855-1.172, p=0.989), demonstrating that adding moxifloxacin to the recommended regimen does not cause more adverse events during TB treatment. This meta-analysis suggests that the introduction of moxifloxacin into the recommended regimen for the treatment of non-drug resistant TB improves the clinical outcome by elevating the culture conversion ra...Continue Reading
References
Oct 8, 1999·The Journal of Antimicrobial Chemotherapy·S H Gillespie, O Billington
Mar 16, 2001·Current Opinion in Investigational Drugs·J F Barrett
Nov 16, 2001·Antimicrobial Agents and Chemotherapy·N LounisJ Grosset
May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
Apr 7, 2009·Lancet·Marcus B CondeRichard E Chaisson
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Aug 15, 2009·Current Medical Research and Opinion·Steven Simoens
Nov 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James A SeddonH Simon Schaaf
Jan 13, 2012·PloS One·Marianne E VisserGary Maartens
Jan 20, 2012·International Journal of Clinical Practice·Y P MuY Wang
May 1, 2013·Nature Reviews. Drug Discovery·Alimuddin ZumlaStewart T Cole
Jul 12, 2013·PloS One·Mohideen S JawaharParanji R Narayanan
Jul 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Banurekha V VelayuthamJawahar M Shaheed
Sep 10, 2014·The New England Journal of Medicine·Stephen H GillespieUNKNOWN REMoxTB Consortium
Oct 23, 2014·The New England Journal of Medicine·Amina JindaniUNKNOWN RIFAQUIN Trial Team
Mar 22, 2015·Lancet·Rodney DawsonCarl M Mendel
Mar 24, 2015·Tuberculosis·S TheeH S Schaaf
Mar 27, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·J D FonsecaT D McHugh
May 13, 2015·Tuberculosis·Zhi ChenGuang-Yu Zhang
Citations
Oct 16, 2019·Antimicrobial Agents and Chemotherapy·Samantha DonnellanGiancarlo A Biagini
Jun 23, 2020·Medicine·Yanmin Guan, Yong Liu
Oct 7, 2018·BMC Infectious Diseases·Liesbeth F MierasMarieke G G Sturkenboom
Nov 3, 2020·Chemistry, an Asian Journal·Chitrala Teja, Fazlur Rahman Nawaz Khan
Aug 24, 2021·Antimicrobial Agents and Chemotherapy·Deepika Rai, Sarika Mehra